Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H ( (HK:1276) ) is now available.
Jiangsu Hengrui Pharmaceuticals Co., Ltd. announced that shareholders overwhelmingly approved proposed amendments to the company’s Articles of Association at its second extraordinary shareholders’ meeting of 2025, held on 31 December in Shanghai. The resolution was passed as a special resolution by poll, winning 99.95% of votes cast, with more than 56% of the company’s voting share capital represented at the meeting, underscoring broad shareholder support and paving the way for the governance and structural changes set out by the board, which may influence the company’s future strategic direction and regulatory alignment.
The most recent analyst rating on (HK:1276) stock is a Buy with a HK$96.90 price target. To see the full list of analyst forecasts on Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H stock, see the HK:1276 Stock Forecast page.
More about Jiangsu Hengrui Pharmaceuticals Co., Ltd. Class H
Jiangsu Hengrui Pharmaceuticals Co., Ltd. is a major Chinese pharmaceutical company engaged in the research, development, manufacturing and sale of innovative drugs and generic medicines, with its shares listed in both A-share and H-share markets and a strong presence in domestic and international healthcare markets.
Average Trading Volume: 3,528,732
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$443.6B
For a thorough assessment of 1276 stock, go to TipRanks’ Stock Analysis page.